Table 3.
Subgroup analysis of patients with CPS ≥ 1.
| Characteristic | Clinical benefit (n, row%) | p value (Fisher exact test) | Odds ratio (95% CI) | |
|---|---|---|---|---|
| CB | NCB | |||
| 11q13 amplification | ||||
| No | 46 (69.7) | 20 (30.3) | 0.004 | 24.95 (1.32, 472.62) |
| Yes | 0 (0) | 5 (100) | ||
| EGFR amplification | ||||
| No | 42 (64.6) | 23 (35.4) | 1.000 | 0.91 (0.16, 5.37) |
| Yes | 4 (66.7) | 2 (33.3) | ||
| EGFR mutation | ||||
| No | 46 (66.7) | 23 (33.3) | 0.121 | 9.89 (0.46, 214.55) |
| Yes | 0 (0) | 2 (100) | ||
CB, clinical benefit; NCB, non-clinical benefit; CPS, combined positive score; 11q13: CCND1_FGF3_FGF4_FGF19 or any one of them.